Kaken

AZ divests European rights for cholesterol med Crestor to Grünenthal

AZ will continue to sell the drug in countries not included in the agreement, including North America, Japan and China.

Biogen signs $3.1bn deal with Sage for potential depression therapies

Outside the US, Biogen will hold responsibility for development and commercialisation with respect to zuranolone, excluding Japan, Taiwan and South Korea.

BMS’ Opdivo wins EU approval for second-line oesophageal cancer

Opdivo (nivolumab) first gained approval in this setting in February, after Japan’s Ministry of Health, Labour and Welfare (MHLW) approved the checkpoint inhibitor for unresectable advanced, or recurrent oesophageal cancer

Pfizer, BioNTech to submit emergency use request for COVID-19 vaccine to FDA today

Rolling submissions for BNT162b2 are already ongoing in a number of regions globally, including the UK, the EU, Australia, Canada and Japan.

Roche’s flu pill Xofluza moves closer towards EU approval

Xofluza was originally discovered and developed by Japanese pharma company Shionogi, which retains the rights to Xofluza in Japan and Taiwan – Roche holds the remaining worldwide rights to the drug.

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]